头孢曲松与青霉素G治疗神经梅毒的法国多中心回顾性研究
该回顾性多中心研究纳入法国8家三级中心1997–2017年208例神经梅毒患者,比较头孢曲松与青霉素G的疗效。结果显示两组1个月总体临床缓解率经倾向评分加权后仍有差异,6个月血清学反应无差异,头孢曲松组住院时间更短,无严重不良反应。
要点
- 头孢曲松治疗神经梅毒的总体临床缓解率在倾向评分加权后仍与青霉素G存在差异。
- 两组6个月血清学反应无显著差异,头孢曲松组住院时间更短。
- 两种治疗均未报告严重不良反应,但结论需随机对照试验证实。
核心结论
- 头孢曲松治疗神经梅毒的效果与青霉素G相似,且可能缩短住院时间。
研究设计与样本
- 回顾性多中心研究,纳入法国8家三级中心1997年1月1日至2017年12月31日治疗的208例神经梅毒患者。
- 患者按初始治疗分为头孢曲松组(42例)和青霉素G组(166例)。
关键数值与推荐
- 神经梅毒定义:梅毒螺旋体和非螺旋体试验阳性,且满足耳梅毒、眼梅毒、神经系统症状伴脑脊液VDRL或PCR阳性、或脑脊液细胞计数白细胞>5个/μL中至少一项。
- 主要结局为治疗开始后1个月总体临床反应(完全或部分缓解)。
临床怎么用
- 头孢曲松可作为神经梅毒的替代治疗选择,尤其需缩短住院时间时。
- 治疗选择应结合患者具体情况,并关注1个月临床反应和6个月血清学反应。
局限性
- 回顾性设计,组间样本量差异大(头孢曲松组42例 vs 青霉素G组166例)。
- 作者指出需随机对照试验确认结果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Intravenous benzylpenicillin is the gold-standard treatment for neurosyphilis, but it requires prolonged hospitalisation. Ceftriaxone is a possible alternative treatment, the effectiveness of which remains unclear. We aimed to assess the effectiveness of ceftriaxone compared with benzylpenicillin in the treatment of neurosyphilis. METHODS: We did a retrospective multicentre study including patients with neurosyphilis who were treated at one of eight tertiary care centres in France, from Jan 1, 1997, to Dec 31, 2017. We defined neurosyphilis as positive treponemal and non-treponemal tests and at least one of otic syphilis, ocular syphilis, either neurological symptom with a positive result on cerebrospinal fluid (CSF)-VDRL or CSF-PCR tests, or more than five leukocytes in a CSF cell count. Patients with neurosyphilis were identified from the medical information department database of each centre and assigned to one of two groups on the basis of the initial treatment received (ie, benzylpenicillin group or ceftriaxone group). The primary outcome was the overall clinical response (ie, proportion of patients with a complete or partial response) 1 month after treatment initiation. The secondary endpoints were proportions of patients with a complete response at 1 month and serological response at 6 months, and length of hospital stay. FINDINGS: Of 365 patients with a coded diagnosis of neurosyphilis in one of the eight care centres during 1997-2017, 208 were included in this study (42 in the ceftriaxone group and 166 in the benzylpenicillin group). The mean age of patients was 44·4 years (SD 13·4), and 193 (93%) were men. We observed 41 instances of overall clinical response (98%) in the ceftriaxone group versus 125 (76%) in the benzylpenicillin group (crude odds ratio [OR] 13·02 [95% CI 1·73-97·66], p=0·017). After propensity score weighting, overall clinical response rates remained different between the groups (OR 1·22 [95% CI 1·12-1·33], p<0·0001). 22 (52%) patients in the ceftriaxone group and 55 (33%) in the benzylpenicillin group had a complete response (crude OR 2·26 [95% CI 1·12-4·41], p=0·031), with no significant difference after propensity score weighting (OR 1·08 [95% CI 0·94-1·24], p=0·269). Serological response at 6 months did not differ between the groups (21 [88%] of 24 in the ceftriaxone group vs 76 [82%] of 93 in the benzylpenicillin group; crude OR 1·56 [95% CI 0·42-5·86], p=0·50), whereas hospital stay was shorter for patients in the ceftriaxone group than for those in the benzylpenicillin group (mean 13·8 days [95% CI 12·8-14·8] vs 8·9 days [5·7-12·0], p<0·0001). No major adverse effects were reported in either group. INTERPRETATION: Our results suggest that ceftriaxone is similarly effective to benzylpenicillin for the treatment of neurosyphilis, potentially decreasing the length of hospital stay. Randomised, controlled trials should be done to confirm these results. FUNDING: None.
引用
- Bettuzzi T, Jourdes A, Robineau O, et al. Ceftriaxone compared with benzylpenicillin in the treatment of neurosyphilis in France: a retrospective multicentre study. Lancet Infect Dis. 2021. PMID: 34051142. doi:10.1016/S1473-3099(20)30857-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。